Title |
Molecular docking analysis of imiquimod with the TGF-β targets for oral carcinoma |
Authors |
Jayanthi Pazhani, Vishnu Priya Veeraraghavan & Selvaraj Jayaraman* |
Affiliation |
Centre of Molecular Medicine and Diagnostics (COMManD), Department of Biochemistry, Saveetha Dental College & Hospitals, Saveetha Institute of Medical & Technical Sciences, Saveetha University, Chennai-600077, India; *Corresponding author |
|
Jayanthi Pazhani - drjayanthip@gmail.com Vishnu Priya Veeraraghavan -vishnupriya@saveetha.com Selvaraj Jayaraman - selvarajj.sdc@saveetha.com
|
Article Type |
Research Article
|
Date |
Received April 1, 2023; Revised April 30, 2023; Accepted April 30, 2023, Published April 30, 2023
|
Abstract |
TGF-β signalling pathway is the main signalling pathways that regulate various biological functions such as cell proliferation, apoptosis, metabolic dysregulation, and metastasis in many cancer cells. Previous studies have elaborated the role of TGF-β signalling targets have a significant regulatory function in various cancers. Moreover targeting the epithelial to mesenchymal transition markers in oral squamous cell carcinoma not yet elucidated. Therefore, it is of interest to document the molecular docking analysis of TGF-β signalling pathway targets such as Smad2, GATA2 and MAFG with imiquimod. These results suggest that targeting the TGF-β signaling pathway downstream targets with imiquimod might leads to an improved outcome as potential therapeutic options in oral carcinoma. |
Keywords |
Oral cancer, TGF-β signaling, Imiquimod, molecular docking
|
Citation |
Pazhani et al. Bioinformation 19(4): 467-470 (2023)
|
Edited by |
P Kangueane
|
ISSN |
0973-2063
|
Publisher |
|
License |
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
|
|